Silver nanoparticles and their antibacterial applications
Author
dc.contributor.author
Bruna, Tamara
Author
dc.contributor.author
Maldonado Bravo, Francisca
Author
dc.contributor.author
Jara Vergara, Paul Sebastián
Author
dc.contributor.author
Caro, Nelson
Admission date
dc.date.accessioned
2021-10-25T13:37:09Z
Available date
dc.date.available
2021-10-25T13:37:09Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Int. J. Mol. Sci. 2021, 22, 7202
es_ES
Identifier
dc.identifier.other
10.3390/ijms22137202
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/182370
Abstract
dc.description.abstract
Silver nanoparticles (AgNPs) have been imposed as an excellent antimicrobial agent being
able to combat bacteria in vitro and in vivo causing infections. The antibacterial capacity of AgNPs
covers Gram-negative and Gram-positive bacteria, including multidrug resistant strains. AgNPs
exhibit multiple and simultaneous mechanisms of action and in combination with antibacterial agents
as organic compounds or antibiotics it has shown synergistic effect against pathogens bacteria such
as Escherichia coli and Staphylococcus aureus. The characteristics of silver nanoparticles make them
suitable for their application in medical and healthcare products where they may treat infections or
prevent them efficiently. With the urgent need for new efficient antibacterial agents, this review aims
to establish factors affecting antibacterial and cytotoxic effects of silver nanoparticles, as well as to
expose the advantages of using AgNPs as new antibacterial agents in combination with antibiotic,
which will reduce the dosage needed and prevent secondary effects associated to both.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT 1171611
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States